SEP 16, 2019 12:39 PM PDT

Injectable Hydrogel Found Safe for Heart Repair

WRITTEN BY: Nouran Amin

The first successful in-human clinical trial of an injectable hydrogel that aims to repair heart damage and restore cardiac function was recently conducted by Ventirx—a University of San Diego spin-off company. The clinical trial was an FDA-approved Phase 1 study targeted for heart failure patients who recently suffered cardiac arrest. The study was the first to test an injectable hydrogel made to improve cardiac tissue. The hydrogel was made form a natural scaffolding of cardiac muscle tissue known as the heart tissues extracellular matrix, or ECM. This is especially crucial because studies shave shown that ECM hydrogels are highly effective for other conditions such as poor blood circulation from peripheral artery disease.

Findings of the injectable hydrogel, known as VentriGel, has been reported in the latest issue of American College of Cardiology. Following heart attack, the study examined 15 patients who sustained moderate damage in the left ventricle chamber of the heart. Each one of those patients received up to 18 injections of VentriGel into the damaged areas.

"Although the study was designed to evaluate safety and feasibility and not designed to show whether VentriGel effectively helps improve heart function, we observed some improvements in patients," said Karen Christman, the paper's senior author and a professor of bioengineering in the Jacobs School of Engineering and the Institute of Engineering in Medicine at UC San Diego. "For example, patients could walk longer distances. We also observed signs of improving heart function in patients who experienced a heart attack more than one year prior to treatment."

Karen Christman, professor in the Department of Bioengineering at UC San Diego, led the development of Ventrigel, a hydrogel to repair heart tissue after heart attacks.

(CREDIT: University of California-San Diego)

In patients who suffered a heart attack within the past 2 to 36 months, VentriGel can be injected in a safe manner through a catheter. Once in, the damaged cardiac muscle can be repaired from the scaffold presented by the VentriGel. This allows healthy cells to migrate, more cardiac muscle formation, less scar tissue, and improvements in cardiac function.

VentriGel is made from the cardiac connective tissue of pigs, which is cleansed of heart muscle cells through a detailed process and then freeze-dried and milled into powder form. After, the powder becomes liquid and is then is ready to be injected in the heart muscle. The minimally invasive procedure will take the liquid and convert it to a gel once it reaches body temperature.

Watch this video below to learn more:

Positive results of the study are now allowing researchers to prepare for the Phase 2 clinical trial which will allow them to determine how VentriGel can improve the quality of life for heart failure patients.

Source: University of California-San Diego

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 16, 2020
Cannabis Sciences
MAY 16, 2020
Body's Own Cannabis Helps Us Forget Traumatic Events
Researchers have found that anandamide, often referred to as the body’s own cannabis, may help us forget traumatic ...
MAY 19, 2020
Drug Discovery & Development
MAY 19, 2020
Can Chinese Drug Cure COVID-19 Without Vaccine?
Researchers at China’s Peking University have announced that they are developing a treatment capable of blocking C ...
MAY 26, 2020
Drug Discovery & Development
MAY 26, 2020
Everyone Can Produce Antibodies Against COVID-19
Researchers at Rockefeller University in New York have found that most people exposed to COVID-19, and who experience sy ...
JUN 06, 2020
Cancer
JUN 06, 2020
Developing a Platform to Efficiently Test Antibody-Drug Conjugates
Cancer has been one of the most persistent diseases modern medicine has faced. Due to its nature, treatments are often t ...
JUN 18, 2020
Drug Discovery & Development
JUN 18, 2020
FDA Cancels Emergency Approval for Hydroxychloroquine
The US Food and Drug Administration (FDA) has decided to cancel emergency use authorization for Hydroxychloroquine and C ...
JUN 17, 2020
Drug Discovery & Development
JUN 17, 2020
Treating Atherosclerosis
The two main proponents for atherosclerotic plaque and inflammation is an increase in cholesterol and macrophage presenc ...
Loading Comments...